Revenue
No reported data
Acrivon Therapeutics, Inc. (ACRV)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Research & development | $60.0M | $64.0M | $46.0M | $23.9M | — |
| Operating expenses | $84.1M | $89.2M | $67.1M | $32.7M | $16.2M |
| Operating income | −$84.1M | −$89.2M | −$67.1M | −$32.7M | −$16.2M |
| Net income | −$77.9M | −$80.6M | −$60.4M | −$31.2M | −$16.2M |
| Basic EPSper diluted share | -$2.02 | -$2.38 | -$2.74 | -$7.56 | -$9.32 |
| Diluted EPSper diluted share | -$2.02 | -$2.38 | -$2.74 | -$7.56 | -$9.32 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 14, 2026Form 4 | Blume-Jensen Peter +1President and CEO | BuyCommon Stock | 49.0K | $1.68 | $82.3K | 2.10M |
| Jan 14, 2026Form 4 | Levy Adam D.Chief Financial Officer | BuyCommon Stock | 8.8K | $1.70 | $15.0K | 21.0K |
| Jan 13, 2026Form 4 | Devroe EricChief Operating Officer | BuyCommon Stock | 10.0K | $1.72 | $17.2K | 75.3K |
| May 1, 2025Form 4 | PERCEPTIVE ADVISORS LLC +2TenPercentOwner | SellCommon Stock · indirect | 298.9K | $1.34 | $400.5K | 3.10M |
| Apr 30, 2025Form 4 | PERCEPTIVE ADVISORS LLC +2TenPercentOwner | SellCommon Stock · indirect | 437.9K | $1.41 | $617.4K | 3.40M |